Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

35 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
Identification of predictive factors of response to the BH3-mimetic molecule ABT-737: an ex vivo experiment in human serous ovarian carcinoma.
Lheureux S, N'Diaye M, Blanc-Fournier C, Dugué AE, Clarisse B, Dutoit S, Giffard F, Abeilard E, Briand M, Labiche A, Grellard JM, Crouet H, Martin S, Joly F, Poulain L. Lheureux S, et al. Int J Cancer. 2015 Mar 1;136(5):E340-50. doi: 10.1002/ijc.29104. Epub 2014 Aug 8. Int J Cancer. 2015. PMID: 25066666 Free article.
Atelocollagen-mediated in vivo siRNA transfection in ovarian carcinoma is influenced by tumor site, siRNA target and administration route.
Meryet-Figuière M, Lecerf C, Varin E, Coll JL, Louis MH, Dutoit S, Giffard F, Blanc-Fournier C, Hedir S, Vigneron N, Brotin E, Pelletier L, Josserand V, Denoyelle C, Poulain L. Meryet-Figuière M, et al. Oncol Rep. 2017 Oct;38(4):1949-1958. doi: 10.3892/or.2017.5882. Epub 2017 Aug 4. Oncol Rep. 2017. PMID: 28791387 Free PMC article.
Functional miRNA Screening Identifies Wide-ranging Antitumor Properties of miR-3622b-5p and Reveals a New Therapeutic Combination Strategy in Ovarian Tumor Organoids.
Vernon M, Lambert B, Meryet-Figuière M, Brotin E, Weiswald LB, Paysant H, Vigneron N, Wambecke A, Abeilard E, Giffard F, Louis MH, Blanc-Fournier C, Gauduchon P, Poulain L, Denoyelle C. Vernon M, et al. Mol Cancer Ther. 2020 Jul;19(7):1506-1519. doi: 10.1158/1535-7163.MCT-19-0510. Epub 2020 May 5. Mol Cancer Ther. 2020. PMID: 32371581
A phase II study of Navitoclax (ABT-263) as single agent in women heavily pretreated for recurrent epithelial ovarian cancer: The MONAVI - GINECO study.
Joly F, Fabbro M, Follana P, Lequesne J, Medioni J, Lesoin A, Frenel JS, Abadie-Lacourtoisie S, Floquet A, Gladieff L, You B, Gavoille C, Kalbacher E, Briand M, Brachet PE, Giffard F, Weiswald LB, Just PA, Blanc-Fournier C, Leconte A, Clarisse B, Leary A, Poulain L. Joly F, et al. Among authors: blanc fournier c. Gynecol Oncol. 2022 Apr;165(1):30-39. doi: 10.1016/j.ygyno.2022.01.021. Epub 2022 Feb 2. Gynecol Oncol. 2022. PMID: 35123771 Clinical Trial.
35 results